Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
SAN FRANCISCO, Nov. 23, 2016 -- Hagens Berman Sobol Shapiro LLP alerts investors in Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) to the securities class action filed in the U.S. District Court for the Southern District of California and the January 17, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired Ligand shares between November 9, 2015 and November 14, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/LGND
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On November 3, 2016, Ligand announced it was evaluating how it accounted for certain deferred tax assets (“DTA”) recorded in the third quarter of 2015. The Company explained, “the amount of DTA Ligand recorded in connection with the release of its valuation allowance could be reduced by approximately 10% of the $217 million DTA booked in the third quarter of 2015[]” and “[t]he impact of the reduction would reduce ... GAAP net income for that period by the same amount.”
On November 14, 2016, Ligand revealed it overstated its DTA by approximately $27.5 million (over 26% higher than first announced) and misclassified certain debt as short-term debt rather than long-term debt as of December 31, 2015.
“We’re investigating Ligand’s debt misclassification, insider sales, and when management knew it was improbable that the Company would recover its DTA completely,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Ligand should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
